Tenet Healthcare (NYSE:THC) Price Target Cut to $225.00 by Analysts at KeyCorp

Tenet Healthcare (NYSE:THC) had its price objective reduced by KeyCorp from $250.00 to $225.00 in a research report sent to investors on Friday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

A number of other analysts also recently issued reports on THC. TD Cowen reaffirmed a “buy” rating on shares of Tenet Healthcare in a research report on Thursday, February 12th. Mizuho raised their price target on Tenet Healthcare from $235.00 to $265.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Wells Fargo & Company reiterated an “overweight” rating and set a $265.00 price objective on shares of Tenet Healthcare in a research note on Monday, February 16th. Morgan Stanley reissued an “overweight” rating and issued a $260.00 target price on shares of Tenet Healthcare in a research note on Thursday, February 12th. Finally, Jefferies Financial Group upped their price target on shares of Tenet Healthcare from $250.00 to $265.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $241.94.

Tenet Healthcare Stock Up 3.5%

Shares of THC traded up $6.11 during mid-day trading on Friday, hitting $183.23. 3,327,802 shares of the company’s stock were exchanged, compared to its average volume of 1,400,520. The company has a 50-day simple moving average of $207.31 and a 200 day simple moving average of $204.17. The company has a debt-to-equity ratio of 1.96, a current ratio of 1.36 and a quick ratio of 1.68. The company has a market cap of $16.05 billion, a PE ratio of 11.83, a P/E/G ratio of 1.32 and a beta of 1.30. Tenet Healthcare has a 52 week low of $145.27 and a 52 week high of $247.21.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, April 30th. The company reported $4.82 EPS for the quarter, topping the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The business had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.39 billion. During the same quarter in the prior year, the company posted $4.36 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, research analysts forecast that Tenet Healthcare will post 17.41 earnings per share for the current fiscal year.

Insider Activity at Tenet Healthcare

In other news, insider R. Scott Ramsey sold 8,017 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $232.70, for a total value of $1,865,555.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Paola M. Arbour sold 6,500 shares of Tenet Healthcare stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the sale, the executive vice president directly owned 29,291 shares of the company’s stock, valued at $6,983,853.13. The trade was a 18.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 46,517 shares of company stock worth $10,943,111. Company insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Tenet Healthcare

A number of institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in shares of Tenet Healthcare during the fourth quarter worth approximately $248,494,000. Eminence Capital LP bought a new stake in Tenet Healthcare in the 3rd quarter valued at $225,263,000. Wellington Management Group LLP grew its holdings in Tenet Healthcare by 1,114.2% in the 4th quarter. Wellington Management Group LLP now owns 1,135,801 shares of the company’s stock valued at $225,706,000 after buying an additional 1,042,260 shares in the last quarter. Boston Partners increased its position in Tenet Healthcare by 38.8% during the 3rd quarter. Boston Partners now owns 3,147,555 shares of the company’s stock worth $638,958,000 after buying an additional 880,413 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of Tenet Healthcare by 62.3% in the third quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock valued at $380,989,000 after acquiring an additional 720,160 shares during the period. Institutional investors own 95.44% of the company’s stock.

Key Headlines Impacting Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Q1 earnings beat and solid profitability — Tenet reported $4.82 EPS, well ahead of consensus, and showed healthy margins and ROE; investors favor the earnings beat even though revenue was roughly in-line. Tenet Healthcare (THC) Q1 Earnings Top Estimates
• Positive Sentiment: Strategic growth via ASC acquisitions — Tenet deployed ~$125M to acquire seven ambulatory surgery centers in Q1 and signals more M&A in the outpatient space, supporting revenue diversification and higher-margin outpatient growth. Tenet deployed $125M on 7 ASC acquisitions in Q1, eyes more deals
• Positive Sentiment: Operational momentum in procedures and robotics — The company is seeing double?digit joint replacement growth and expanding robotic programs across ASCs/hospitals, evidence that its outpatient acuity push is producing revenue mix benefits longer term. Double-digit joint replacement growth
• Neutral Sentiment: Analysts trimmed price targets but kept Buy/Outperform/Overweight ratings — Multiple firms cut PTs (RBC to $236, Guggenheim to $252, Wells Fargo to $213, KeyCorp to $225) while retaining positive ratings, which gives the stock continued sell?side endorsement but signals more conservative valuation assumptions. Analyst price target coverage (Benzinga summaries) TickerReport coverage
• Neutral Sentiment: Market commentary and investor takeaways — Several pieces are advising investors to weigh analyst views and the company’s outpatient strategy at current levels; these articles are shaping investor positioning rather than delivering new fundamental news. Seeking Alpha: Investor commentary
• Negative Sentiment: Revenue softness and admissions?mix headwinds — Management flagged admissions mix and external disruptions as reasons revenue missed expectations modestly; that weak revenue signal tempers the EPS beat and is the main near-term risk. Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.